©The Author(s) 2026.
World J Methodol. Mar 20, 2026; 16(1): 111566
Published online Mar 20, 2026. doi: 10.5662/wjm.v16.i1.111566
Published online Mar 20, 2026. doi: 10.5662/wjm.v16.i1.111566
Figure 1
PRISMA flowchart outlining the literature screening process, study selection, and exclusion criteria.
Figure 2 Forest plots comparing outcomes between sirolimus-coated balloon and paclitaxel-coated balloon in in-stent restenosis patients.
A: Target lesion revascularization; B: Stent thrombosis; C: Major adverse cardiovascular events; D: All-cause mortality; E: Cardiac mortality; F: Myocardial infarction.
- Citation: Mandal D, Pulickal TV, Ahlawat D, Haqbeen W, Kashif I, Alamy H, Prattipati P, Jaladi P, Kabiaru P, Avula A, Kshetri S, Raza I, Shamieh S, Chhetri R. Sirolimus vs paclitaxel-coated balloons in in-stent coronary restenosis: A meta-analysis. World J Methodol 2026; 16(1): 111566
- URL: https://www.wjgnet.com/2222-0682/full/v16/i1/111566.htm
- DOI: https://dx.doi.org/10.5662/wjm.v16.i1.111566